-+ 0.00%
-+ 0.00%
-+ 0.00%

ABBVIE ANNOUNCES TOPLINE RESULTS FROM THE PHASE 3 INTREPID TRIAL SHOWING LUTIKIZUMAB SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF DISEASE IN PATIENTS WITH HIDRADENITIS SUPPURATIVA

Reuters·10/22/2026 13:00:08

Please log in to view news